-1754336787371.webp&w=3840&q=75)
2025 NOSCM | Irreversible Accomplishments in Glioma Management – Is it “Fait Accompli”?
Overview
Dr. Choudhury discussed glioma care advances, highlighting IDH inhibitors like vorasidenib and the need for next-gen sequencing for non-canonical mutations. He cited ongoing trials at Tampa General and emphasized surgery, brachytherapy, and continued research to address tumor heterogeneity.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Sajeel Chowdhary, MD, FAAN, MBBS
Date of Release
July 20th, 2025
